GlassScriptPhysician profile
Emily R Engel
NPI 1093787038
$127,351.33
in general payments reported to CMS, 2019-2025
50 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $25K · 2021: $43K · 2022: $14K · 2023: $7,723 · 2024: $9,102 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $9,219 · Consulting Fee: $2,406 · Travel and Lodging: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,431.25 |
| Food and Beverage | $9,218.86 |
| Consulting Fee | $2,406.25 |
| Travel and Lodging | $128.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,898.34 | 2021-2025 | |
| Allergan, INC. | $20,898.75 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $12,154.83 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $10,191.43 | 2021 | |
| Amgen INC. | $7,020.16 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $5,906.28 | 2019-2025 | Emgality, Reyvow |
| Lundbeck LLC | $5,882.67 | 2020-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $4,098.41 | 2022 | |
| Pfizer INC. | $922.76 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $746.52 | 2019-2025 | |
| Ucb, INC. | $333.99 | 2019-2025 | Zilbrysq, Briviact |
| Sunovion Pharmaceuticals INC. | $301.68 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $266.07 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $192.43 | 2019-2020 | |
| Impel Pharmaceuticals LLC | $183.21 | 2024-2025 | Trudhesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Engel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.